Clear Search

Showing 23 results for “cardiovascular” published 2022.

May 2022

Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients With Type 2 Diabetes at High Cardiovascular Risk: The SIMPLE Trial

Diabetes 2022;71:812–20 doi.org/10.2337/db21-0721

In this analysis of data from the SIMPLE trial, empagliflozin did not reduce left heart filling pressure more than placebo at submaximal exercise in patients with T2D at high CV risk. However, it was observed that empagliflozin reduced pulmonary capillary wedge pressure (PCWP) at a magnitude of clinical significance in patients at rest. The findings suggest cardiac benefits beyond the diuretic effect of sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and could explain a significant part of the CV benefits observed in clinical trials.

more…

Initial Decline (“Dip”) in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF

Circulation 2022; Online ahead of print doi: 10.1161/CIRCULATIONAHA.121.058910

The results of this subgroup analysis from DAPA-HF show that – although estimated glomerular filtration rate (eGFR) decline is generally associated with poorer prognosis in most situations – an initial dip with a sodium-glucose co-transporter-2 inhibitor (SGLT2i) may be associated with slower rate of decline in kidney function.

more…

The Comparative Cardiovascular and Renal Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Scandinavian Cohort Study

Diabetes Obes Metab 2022;24:473–85 doi: 10.1111/dom.14598

In this study by Ueda et al., SGLT2 inhibitors were associated with a similar risk of heart failure and a lower risk of serious renal events compared with GLP-1 receptor agonist,s and the use of GLP-1 receptor agonists was associated with a slightly lower risk of MACE compared with SGLT2 inhibitors.

more…

March 2022

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus

Endocrinol Metab 2022;37:170–4; doi.org/10.3803/EnM.2021.1296

Finerenone induced a 13% risk reduction in MACE (a composite of death from CV causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for heart failure) regardless of prior glycaemia. There was no difference in finerenone-derived MACE benefits whether patients were on baseline SGLT2i or GLP-1RA or not.

more…

Effects of Canagliflozin Versus Finerenone on Cardiorenal Outcomes: Exploratory Post-Hoc Analyses From FIDELIO-DKD Compared to Reported CREDENCE Results

Nephrol Dial Transplant 2021;gfab336 doi: 10.1093/ndt/gfab366

Finerenone and canagliflozin reduce cardiorenal risk in patients who are albuminuric. This exploratory post-hoc analyses by Agarwal et al. investigated how differences in trial design influenced observed treatment effects in the FIDELIO-DKD and CREDENCE studies.

more…

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

N Engl J Med 2021;385:2252–63 doi: 10.1056/NEJMoa2110956

Finerenone has desirable effects on cardiorenal outcomes in patients with stage 3 or 4 chronic kidney disease (CKD), type 2 diabetes and severely elevated albuminuria. The outcomes of the use of finerenone are unclear in patients with type 2 diabetes and a wider range of CKD. 

more…

Keywords:

January 2022

Effects of canagliflozin with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c disease duration and treatment intensity: results from the CANVAS program

Diabetologia. 2021;64:2402–14 doi.org/10.1007/s00125-021-05524-1

This study by Young et al. shows canagliflozin to have beneficial CV and kidney outcomes in patients with T2DM across a range of diabetes complexities with an underlying risk of CV disease.

more…

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

N Engl J Med 2019;380:347–57 DOI 10.1056/NEJMoa1812389

Dapagliflozin was found to be noninferior to placebo in terms of major adverse cardiovascular events in the DECLARE-TIMI 58 trial.

more…

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

N Engl J Med 2020;383:1413–24 DOI 10.1056/NEJMoa2022190

Empagliflozin demonstrated a reduction in CV death, HF hospitalisation, rate of eGFR decline and risk of serious renal outcomes in patients with chronic HF and reduced ejection fraction in the EMPEROR-reduced study.

more…